Immunogenicity Assessment

What is Immunogenicity Assessment?

Immunogenicity refers to the ability of an antigen to induce an immune response, directly impacting the safety, efficacy, and protective immunity of a vaccine.

The primary goal of immunogenicity assessment is to ensure that a vaccine can activate a specific immune response, helping individuals establish immune memory against pathogens without triggering adverse reactions or hypersensitivity. This critical step in vaccine development allows researchers to evaluate antigen responses, as well as the strength, type, and role of antibodies, T cells, and other immune responses in immune defense.

We can say, effective immunogenicity assessment is an essential foundation for vaccine development and regulatory approval.

Figure 1. Influenza HA peptide array antibody reactivity correlates with age/post-vaccine neutralization titer. (Source: Price JV, et al. 2013)

Complete Every Stage of Immunogenicity Assessment with Our Protein Biochip Technology

At Creative Diagnostics, our advanced Protein Biochip platform offers efficient and precise solutions for immunogenicity assessment, covering all steps from antigen screening to dynamic immune response monitoring. Here's how our platform can support your research:

High-Throughput Screening and Immune Response Monitoring

With our platform, you can evaluate multiple immunogenicity indicators simultaneously in a single experiment, including antibody production, T cell responses, and cytokine secretion. This significantly boosts screening efficiency and shortens experimental timelines.

Accurate Quantitative Analysis of Immunogenicity

By integrating laser confocal imaging and near-infrared fluorescence labeling technologies, our Protein Biochip platform achieves precise detection of antibody affinity, subtype distribution, and neutralizing capacity. Its sensitivity at the picomolar level ensures accurate identification of low-abundance molecules.

Dynamic Tracking of Immune Responses

Beyond static immune detection, our platform supports real-time monitoring of dynamic immune responses. This allows you to capture critical molecular changes during immune reactions, providing insights into potential risks related to immune escape and tolerance.

Comprehensive Data Support for Immunogenicity Assessment

Our platform includes built-in intelligent data analysis tools to help you process high-dimensional data quickly. Generate intuitive analysis reports to streamline decision-making in vaccine development.

Array Example

Panel	Example Combination	Target Application	Possible Sample Preparation
Panel A (Antibody Detection)	- Protein drug (wild-type + mutants) - Vaccine antigen + common contaminants - Detection of IgG subclasses (IgG1, IgG2), IgM, IgA, IgE	- Anti-drug antibody detection (ADA) - Vaccine immunogenicity profiling - Evaluate isotype distribution (possible allergic response via IgE)	- In vitro: Cell culture supernatants (B cell or hybridoma cultures) - In vivo: Serum/plasma from immunized or treated animals/patients at multiple timepoints (day 7, 14, etc.)
Panel B (Cytokine Release)	- Th1: IFN-γ, IL-2 - Th2: IL-4, IL-5, IL-13 - Pro-inflammatory: IL-1β, IL-6, TNF-α - Regulatory: IL-10, TGF-β	- T-cell immunogenicity (skewing toward Th1, Th2, Th17, or Treg) - Detect potential cytokine storm or excessive inflammation	- In vitro: Culture supernatants from PBMCs, T cells, DC co-cultures stimulated with the protein - In vivo: Serum or ex vivo restimulation of splenocytes/lymph node cells
Panel C (Epitope Mapping & Cross-Reactivity)	- Peptide arrays: Overlapping 15–20mer peptides covering the therapeutic/vaccine protein - Self-antigens or proteins from closely related organisms (for cross-reactivity)	- Fine-map immunogenic epitopes - Determine cross-reactivity with host or related pathogens - Guide rational re-engineering of therapeutics to reduce immunogenicity	- In vitro: T-cell assays (proliferation/cytokine release) with each peptide variant - In vivo: Serum tested for antibody binding to each peptide or cross-antigen; also ex vivo T-cell restimulation

Why Creative Diagnostics' Protein Biochip Stands Out?

Cutting-Edge Technology Platform
Combines laser confocal imaging and near-infrared fluorescence labeling to detect immune molecules even at extremely low abundance levels.
Efficient Multi-Indicator Detection
Suitable for multi-pathway analysis of complex immune responses.
Flexible Customization Services
Tailored solutions for specific molecule detection, immune pathway analysis, and optimization of experimental conditions to meet your unique vaccine R&D needs.
International Standards and High Reproducibility
All data comply with international standards and exhibit excellent reproducibility.
Resource-Saving with Low Sample Requirements
Our Protein Biochip requires minimal sample volumes, conserving valuable resources—especially beneficial for early clinical research or rare sample immunogenicity assessments.

Accelerate Your Vaccine Development with Creative Diagnostics

Leverage the precision and efficiency of our Protein Biochip technology for immunogenicity assessment. Gain accurate, high-quality experimental data to accelerate vaccine development, improve research efficiency, and ensure the clinical safety and effectiveness of your vaccines.

Ready to get started? Have questions?

Reference

Price JV, Jarrell JA, Furman D, Kattah NH, Newell E, Davis MM. Characterization of influenza vaccine immunogenicity using influenza antigen microarrays. PLoS One. 2013;8(5):e64555.

Online Inquiry

Name

Phone

* Email

* Products or Services Interested:

Project Description

Services